Cell therapy · Kills target cells · developed by Nanjing Legend Biotech
LCAR-F33S is a cell therapy given after a conditioning regimen of cyclophosphamide and fludarabine, studied in relapsed or refractory multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07100067 | N/A | Relapsed/Refractory Multiple Myeloma(MM) | Recruiting | LEGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed/Refractory Multiple Myeloma(MM)
Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.
See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LEGN catalysts and pipeline →